Kymera Investor Day Presentation Deck

ID We Want to Drug All Target Classes C Inadequately Drugged Targets with Clear Degrader Advantage Small molecule binders exist but unable to drug target fully e.g. IRAK4, MDM2... KYMERA Heterobifunctional Degraders ©2021 KYMERA THERAPEUTICS, INC. Expanding the Druggable Proteome with TPD UD Undrugged Targets No other technology can drug Ligandable Proteins e.g. STAT3... Heterobifunctional Degraders Un-ligandable Proteins e.g. other transcription factors Molecular Glues KYMERA R&D DAY - December 16th, 2021 Clinically Validated Targets TR Enabled by E3 Ligase Tissue Restricted Expression On target unwanted pharmacology limits clinical application Į E3-1 E3-2 Tissue sparing or selective E3 ligases eliminate unwanted toxicity and allow full clinical potential PAGE 87

View entire presentation